U.S. Liposomal Doxorubicin Market Analysis & Forecast: 2026-2033
The U.S. Liposomal Doxorubicin Market size is anticipated to grow at a CAGR of 6.8% with USD 500 Mn in 2026 and is expected to reach USD 780 Mn in 2033. The market is growing with the rising recurrent ovarian cancer burden, continued use of pegylated liposomal doxorubicin in oncology treatment protocols, increasing demand for safer anthracycline delivery systems, and expanding availability of therapeutically equivalent generic formulations. According to the U.S. FDA label, DOXIL liposomal infusion is indicated for ovarian cancer after platinum-based
On the basis of drug type, the generic segment accounts for the largest U.S. Liposomal Doxorubicin Market share of 61.5% in 2026. The growth of the segment is mainly driven by the rising demand for cost-effective oncology therapies, wider payer preference for lower-cost alternatives, and increasing availability of FDA-approved generic liposomal doxorubicin products. According to the U.S. FDA, 9 out of 10 prescriptions filled in the U.S. are for generic drugs, highlighting the strong role of generics in improving treatment affordability and access.
Generic liposomal doxorubicin is widely used as it offers a therapeutically equivalent alternative to branded Doxil for approved oncology indications, including ovarian cancer, multiple myeloma, and AIDS-related Kaposi’s sarcoma. The Association for Accessible Medicines reported that generics and biosimilars account for around 90% of U.S. prescriptions but only 13.1% of prescription drug spending, making them important for oncology cost containment.
To learn more about this report, Request Free Sample
On the basis of cancer type, the ovarian cancer segment accounts for the largest U.S. Liposomal Doxorubicin Market share of 46.8% in 2026. The segment’s growth is owing to the FDA-approved use of liposomal doxorubicin in ovarian cancer after progression or recurrence following platinum-based chemotherapy, continuing recurrent disease burden, and the need for treatment options in patients who have exhausted initial chemotherapy regimens.
SEER estimates 21,010 new ovarian cancer cases and 12,450 deaths in the U.S. in 2026. It reported that 54% of ovarian cancer cases are diagnosed at distant stage, thereby indicating a high burden of advanced disease. The FDA label also includes clinical trial evidence in ovarian cancer including a randomized trial of 474 patients comparing DOXIL liposomal infusion with topotecan after platinum-based chemotherapy. These factors support the continual use in later-line treatment pathways.
In August 2024, Lupin Limited launched Doxorubicin Hydrochloride Liposome Injection in the U.S., following FDA approval secured by alliance partner ForDoz Pharma. The generic Doxil equivalent targets ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma, with USD 40.9 million sales.
The U.S. liposomal doxorubicin market is being transformed by continued generic competition, regulatory pathways for complex injectables, as well as increasing attention to sterile injectable quality. Liposomal doxorubicin is a complex oncology injectable, and market access depends not only on clinical demand but also on manufacturing consistency, FDA approval, vial availability, therapeutic equivalence, and institutional contracting. Generic entry is important because oncology providers and hospital pharmacies seek reliable sources for older injectable cancer therapies that remain clinically relevant but are vulnerable to supply constraints.
In June 2025, Alembic Pharmaceuticals announced that it received USFDA final approval for its ANDA for Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL and 50 mg/25 mL single-dose vials. The company stated that the approved ANDA is therapeutically equivalent to Baxter’s reference listed drug, Doxil Liposome Injection, and cited an estimated U.S. market size of US$29 million for the twelve months ending March 2025.
Pegylated liposomal nanocarrier technology represents the core breakthrough behind liposomal doxorubicin. The technology encapsulates doxorubicin inside liposomes, helping alter pharmacokinetics and drug distribution compared with conventional doxorubicin.
The FDA label highlights the pharmacokinetic distinction of DOXIL liposomal infusion, reporting plasma clearance of total doxorubicin from DOXIL at 0.041 L/h/m² at a 20 mg/m² dose, compared with 24 to 35 L/h/m² following administration of conventional doxorubicin hydrochloride. This difference supports the clinical rationale for using liposomal drug delivery in oncology, particularly where prolonged circulation and altered tissue distribution are desirable.
The technology is also important from a safety-management perspective. The FDA label carries warnings for cardiomyopathy and infusion-related reactions, and it notes that acute infusion-related reactions occurred in 11% of patients with solid tumors across multiple studies. Therefore, innovation is not only focused on efficacy but also on formulation quality, infusion protocols, monitoring, and institutional readiness. Such innovations are expected to accelerate the U.S. liposomal doxorubicin market growth during the forecast period.
|
Current Event |
Description and its Impact |
|
2026 Medicare Part B ASP Pricing and Inflation Rebate Pressure |
|
|
FDA Quality Enforcement and Sterile Injectable Recall Oversight
|
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
California is an important state market owing to its large population, major academic medical centers, cancer research ecosystem, as well as high oncology treatment volumes. The state has several major cancer institutions and hospital systems that support the use of specialized oncology injectables like liposomal doxorubicin. Demand is supported by ovarian cancer treatment pathways, hematology-oncology practices, and institutional procurement through hospital networks.
Texas is a key growth market because of its large population base, major cancer hospitals, growing oncology service capacity, and presence of high-volume infusion centers. The state’s cancer-care ecosystem supports demand for later-line chemotherapy products, including liposomal doxorubicin, particularly in gynecologic oncology and hematology-oncology settings.
Some of the major key players in U.S. Liposomal Doxorubicin Market are Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 500 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.8% | 2033 Value Projection: | USD 780 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
